Erik has over 20 years’ experience in the pharmaceutical and biotechnology industries and joined AM-Pharma in 2007.
Before joining AM-Pharma, Erik was a Senior Executive at Organon where he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships in the industry and raised more than €200M in equity and debt financing for biotechnology companies from seed through IPO. Erik is board member of Lava Therapeutics, Heatmatrix, Lead Pharma, Step Pharma and the Dutch biotechnology organization.
Erik has a Master’s degree in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK), both with distinction.